T 1634/17 (ADAM6 mice/REGENERON PHARMACEUTICALS) vom 25.11.2021
- Europäischer Rechtsprechungsidentifikator
- ECLI:EP:BA:2021:T163417.20211125
- Datum der Entscheidung
- 25. November 2021
- Aktenzeichen
- T 1634/17
- Antrag auf Überprüfung von
- -
- Anmeldenummer
- 12716101.6
- Verfahrenssprache
- Englisch
- Verteilung
- Nicht verteilt (D)
- Download
- Entscheidung auf Englisch
- Amtsblattfassungen
- Keine AB-Links gefunden
- Weitere Entscheidungen für diese Akte
- -
- Zusammenfassungen für diese Entscheidung
- -
- Bezeichnung der Anmeldung
- ADAM6 MICE
- Name des Antragstellers
- REGENERON PHARMACEUTICALS, INC.
- Name des Einsprechenden
- Kymab Limited
- Kammer
- 3.3.08
- Leitsatz
- -
- Relevante Rechtsnormen
- European Patent Convention Art 112European Patent Convention Art 113European Patent Convention Art 123(2)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention R 103(1)(a)Rules of procedure of the Boards of Appeal 2020 Art 012(3)Rules of procedure of the Boards of Appeal Art 12(4)
- Schlagwörter
- Consideration of evidence filed at first instance (yes);
Consideration/admission of evidence filed in appeal (no);
Status of oral/ephemeral disclosure - prior art (no);
Main request - added subject-matter (no);
Main request - sufficiency of disclosure (yes);
Main request - novelty (yes);
Main request - inventive step (yes);
Referral to the Enlarged Board of Appeal (no);
Reimbursement of the appeal fee (no); - Orientierungssatz
- -
Order
For these reasons it is decided that:
1. The request of appellant II (opponent) for referral of questions to the Enlarged Board of Appeal is refused.
2. The decision under appeal is set aside.
3. The opposition is rejected.
4. The request of appellant I (patent proprietor) for reimbursement of the appeal fee is refused.